share_log

Insiders At Genscript Biotech Sold US$12m In Stock, Alluding To Potential Weakness

Insiders At Genscript Biotech Sold US$12m In Stock, Alluding To Potential Weakness

Genscript Biotech內部人士出售了1200萬美元的股票,表明可能存在弱點
Simply Wall St ·  10/29 09:47

Many Genscript Biotech Corporation (HKG:1548) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When evaluating insider transactions, knowing whether insiders are buying is usually more beneficial than knowing whether they are selling, as the latter can be open to many interpretations. However, if numerous insiders are selling, shareholders should investigate more.

在過去的一年裏,許多Genscript Biotech Corporation(HKG:1548)內部人士放棄了他們的股票,這可能會引起公司股東的興趣。 在評估內部交易時,了解內部人員是否在買入通常比了解他們是否在賣出更有益,因爲後者可能會有許多解讀。 但是,如果有許多內部人員在賣出股票,股東應該進行更深入的調查。

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.

雖然我們絕不會建議投資者僅僅基於公司董事們的行動來做決定,但我們認爲跟蹤內部人士的行動是非常合理的。

Genscript Biotech Insider Transactions Over The Last Year

在過去一年裏,Genscript Biotech內部交易

Over the last year, we can see that the biggest insider sale was by the insider, Hong Xin Guo, for HK$7.7m worth of shares, at about HK$22.73 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. It's of some comfort that this sale was conducted at a price well above the current share price, which is HK$12.38. So it is hard to draw any strong conclusion from it.

在過去的一年裏,我們可以看到最大的內部賣出是由內部人士Hong Xin Guo進行的,價值770萬港元的股票,每股約22.73港元。 通常我們不太喜歡看到內部人士賣出,但賣出價格越低,我們就越擔心。 令人稍感安慰的是這次交易的價格遠高於當前股價,即12.38港元。 所以很難從中得出任何堅定的結論。

Insiders in Genscript Biotech didn't buy any shares in the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

Genscript Biotech的內部人員在過去一年裏沒有購買任何股票。 您可以在下面的圖表中看到過去一年內內部交易(由公司和個人)的情況。 點擊下面的圖表,您可以看到每筆內部交易的詳細信息!

big
SEHK:1548 Insider Trading Volume October 29th 2024
1548股票交易所 Insider Trading 成交量 2024年10月29日

For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.

對於那些喜歡發現潛力股票的人,可以免費查看最新內部交易股票的小盤公司名單,這可能正是您要找的機會。

Insiders At Genscript Biotech Have Sold Stock Recently

庚盛生物的內部人士最近出售了股票

Over the last three months, we've seen significant insider selling at Genscript Biotech. In total, Chief Strategy Officer & Executive Director Li Zhu sold HK$1.4m worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain.

在過去的三個月裏,我們看到了庚盛生物內部人員大量拋售股票。在這段時間內,首席策略官兼執行董事李竹出售了價值140萬港元的股份,但我們並沒有記錄到任何購買記錄。鑑於此情況,很難說所有內部人士都認爲這些股票物美價廉。

Insider Ownership

內部人員持股情況

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that Genscript Biotech insiders own 0.2% of the company, worth about HK$52m. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. Whilst better than nothing, we're not overly impressed by these holdings.

查看公司內部股東持股總額可以幫助您了解他們是否與普通股東利益一致。高比例的內部持股往往使公司領導更加關注股東利益。根據我們的數據,Genscript Biotech的內部人士擁有公司的0.2%股份,價值約5200萬港幣。但我們需要注意,內部人士可能通過私人公司或其他公司結構間接持有利益。儘管比無所不有要好,但我們對這些持股並不十分印象深刻。

What Might The Insider Transactions At Genscript Biotech Tell Us?

Genscript Biotech內部交易可能告訴我們什麼?

An insider hasn't bought Genscript Biotech stock in the last three months, but there was some selling. And even if we look at the last year, we didn't see any purchases. While insiders do own shares, they don't own a heap, and they have been selling. We're in no rush to buy! Of course, the future is what matters most. So if you are interested in Genscript Biotech, you should check out this free report on analyst forecasts for the company.

內部人士在過去三個月內沒有購買Genscript Biotech股票,但有一些賣出。即使我們看一下去年的情況,也沒有看到任何購買。雖然內部人士擁有股份,但數量不多,並且一直在賣出。我們不急於買入!當然,最重要的是未來。所以如果您對Genscript Biotech感興趣,您應該查看有關該公司分析師預測的免費報告。

Of course Genscript Biotech may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

當然,Genscript Biotech可能不是您最好的股票購買選擇。因此,您可能希望查看這些高質量公司的免費合集。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論